John Ryan named Senior Vice President and General Counsel at Dana-Farber Cancer Institute

Posted date

    Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14.  
    Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.    

    “John’s sharp mind and deep understanding of the full range of legal issues affecting a complex organization such as Dana-Farber will be a tremendous asset in helping advance our patient care and research goals,” said Laurie H. Glimcher, MD, president and CEO, Dana-Farber Cancer Institute. “I look forward to working with him and the excellent legal team here that he is joining.”

    “I am honored and excited to work with Dr. Glimcher and the leadership team at Dana-Farber to advance the mission of eradicating cancer,” Ryan said. “It is a privilege to have the opportunity to build on the extraordinary work that my predecessor, Richard Boskey, has done to support the world-class patient care and research being done at Dana-Farber, and I look forward to joining their talented and accomplished legal team.”

    Ryan joins Dana-Farber from The Jackson Laboratory, where he served as General Counsel and Corporate Secretary. He previously held similar roles at Unilife Corporation and Aramark Corporation, and was a Partner at the Philadelphia-based law firm Duane Morris LLP.

    Ryan attended New York University, where he graduated with a B.A. cum laude and earned his law degree from Northwestern University. Following law school, John worked as an Assistant District Attorney in Manhattan.  
    Ryan succeeds Richard Boskey, who is retiring as Senior Vice President, General Counsel and Chief Governance Officer after 21 years of service to Dana-Farber.

    Media Contacts

    If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

    The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.